Rituximab for the treatment of post-bone marrow transplantation refractory hemolytic anemia in a child with Omenn's syndrome

Pediatric Transplantation

Volumn 11, Issue 5, 2007, Pages 552-556

  Silvana, Briuglia ^a   Antonella, La Mazza ^a   Basilia, Piraino ^a   Trombetta, Domenico ^a   Saija, Antonella ^a   Salpietro, Carmelo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Autoimmune hemolytic anemia; Bone marrow transplantation; Children; Omenn's syndrome; Rituximab

Indexed keywords

CARDIOLIPIN ANTIBODY; CHLORPHENIRAMINE; CORTICOSTEROID; CYCLOSPORIN; DNA ANTIBODY; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; RAG1 PROTEIN; RITUXIMAB; STEROID;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BONE MARROW TRANSPLANTATION; CASE REPORT; CONTINUOUS INFUSION; COOMBS TEST; DESQUAMATION; FOLLOW UP; GENE MUTATION; GRAFT VERSUS HOST REACTION; HEPATOMEGALY; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LYMPHADENOPATHY; MALE; OMENN SYNDROME; REMISSION; THRUSH; TOXICITY;

ANEMIA, HEMOLYTIC; ANEMIA, REFRACTORY; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; BONE MARROW TRANSPLANTATION; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INFANT; INJECTIONS, INTRAVENOUS; MALE; POSTOPERATIVE COMPLICATIONS; SEVERE COMBINED IMMUNODEFICIENCY; SYNDROME;

EID: 34447336733     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00678.x     Document Type: Article

References (31)

1. Omenn GS. Familial reticuloendotheliosis with eosinophilia. N Engl J Med 1965 : 273 : 427 432.
2. Cooper MA, Pommering TL, Koranyi K. Primary immunodeficiencies. Am Fam Physician 2003 : 68 : 2001 2008.
3. Cooper MD, Lanier LL, Conley ME, Puck JM. Immunodeficiency disorders. Hematology Am Soc Hematol Educ Program 2003 : 314 330.
4. Villa A, Santagata S, Bozzi F, et al. Partial V(D)J recombination activity leads to Omenn syndrome. Cell 1998 : 93 : 885 896.
5. Santagata S, Villa A, Sobacchi C, Cortes P, Vezzoni P. The genetic and biochemical basis of Omenn syndrome. Immunol Rev 2000 : 178 : 64 74.
6. Stiehm ER, Roberts RL, Hanley-Lopez J, et al. Bone marrow transplantation in severe combined immunodeficiency from a sibling who had received a paternal bone marrow transplant. N Engl J Med 1996 : 335 : 1811 1814.
7. Good RA, Verjee T. Historical and current perspectives on bone marrow transplantation for prevention and treatment of immunodeficiencies and autoimmunities. Biol Blood Marrow Transplant 2001 : 7 : 123 135.
8. Buckley RH. Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. Annu Rev Immunol 2004 : 22 : 625 655.
9. Vinzio S, Lioure B, Grunenberger F, Schlienger JL, Goichot B. Auto-immune-like disease post-bone marrow transplantation. Rev Med Interne 2004 : 25 : 514 523.
10. Vargas-Diez E, Garcia-Diez A, Marin A, Fernandez-Herrera J. Life-threatening graft-vs-host disease. Clin Dermatol 2005 : 23 : 285 300.
11. Denianke KS, Frieden IJ, Cowan MJ, Williams ML, McCalmont TH. Cutaneous manifestations of maternal engraftment in patients with severe combined immunodeficiency: A clinicopathologic study. Bone Marrow Transplant 2001 : 28 : 227 233.
12. Appleton AL, Curtis A, Wilkes J, Cant AJ. Differentiation of materno-fetal GVHD from Omenn's syndrome in preBMT patients with severe combined immunodeficiency. Bone Marrow Transplant 1994 : 14 : 157 159.
13. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four dose treatment program. J Clin Oncol 1998 : 16 : 2825 2833.
14. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003 : 101 : 3857 3861.
15. Rastetter W, Molina A, White CA. Rituximab: Expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004 : 55 : 477 503.
16. La Spina M, Russo G. New drugs for childhood anemia. Minerva Pediatr 2003 : 55 : 483 493, 493 498.
17. Zaja F, Vinelli N, Sperotto A, et al. Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases. Leuk Lymphoma 2003 : 44 : 1951 1955.
18. Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur J Haematol 2004 : 72 : 79 88.
19. Virgolini L, Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother 2004 : 58 : 299 309.
20. Nagajothi N, Matsui WH, Mukhina GL, Brodsky RA. Enhanced cytotoxicity of rituximab following genetic and biochemical disruption of glycosylphosphatidylinositol anchored proteins. Leuk Lymphoma 2004 : 45 : 795 799.
21. Hongeng S, Tardtong P, Worapongpaiboon S, Ungkanont A, Jootar S. Successful treatment of refractory autoimmune haemolytic anaemia in a post-unrelated bone marrow transplant paediatric patient with rituximab. Bone Marrow Transplant 2002 : 29 : 871 872.
22. Ramanathan S, Koutts J, Hertzberg MS. Two cases of refractory warm autoimmune hemolytic anemia treated with rituximab. Am J Hematol 2005 : 78 : 123 126.
23. Sibilia J, Sordet C. Rituximab: A original biotherapy in auto-immune disorders. Rev Med Interne 2005 : 26 : 485 500.
24. Gorelik M, Debski R, Frangoul H. Autoimmune hemolytic anemia with giant cell hepatitis: Case report and review of the literature. J Pediatr Hematol Oncol 2004 : 26 : 837 839.
25. Manatadakis E, Danilatou V, Stiakaki E, Kalmanti M. Rituximab for refractory Evans syndrome and other immune-mediated hematologic diseases. Am J Hematol 2004 : 77 : 303 310.
26. Raj A, Bertolone S, Cheerva A. Successful treatment of refractory autoimmune hemolytic anemia with monthly rituximab following non-myeloablative stem cell transplantation for sickle cell disease. J Pediatr Hematol Oncol 2004 : 26 : 312 314.
27. Akyildiz M, Karasu Z, Cagirgan S, Kilic M, Tokat Y. Rituximab therapy for life-threatening immune hemolytic anemia in a liver transplant recipient: A case report. Transplant Proc 2004 : 36 : 1492 1493.
28. Panaro F, DeChristopher PJ, Rondelli D, et al. Severe hemolytic anemia due to passenger lymphocytes after living-related bowel transplant. Clin Transplant 2004 : 18 : 332 335.
29. Wakim M, Shah A, Arndt PA, et al. Successful anti-CD20 monoclonal antibody treatment of severe autoimmune hemolytic anemia due to warm reactive IgM autoantibody in a child with common variable immunodeficiency. Am J Hematol 2004 : 76 : 152 155.
30. Pescovitz MD. The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation. Pediatr Transplant 2004 : 8 : 9 21.
31. Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 2001 : 97 : 3995 3997.